Pharmasaga Company Limited
Update：2025/12/03
Industries
Main Industry
Health Care
Main Product/Service
Currently, Pharmasaga has two Pdia4 inhibitors, PS-001 and PS-002, for type 2 diabetes (T2D) and type 1 diabetes (T1D), respectively. Their pre-clinical studies were completed in 2021.
US FDA approved the application of investigation drug (IND), PS-001. We are scheduled to start phase 1 clinical trial of PS-001 by the third quarter of 2022 and complete it by the end of 2022. Its phase 2 clinical trial is scheduled to start in 2023 and complete it by the end of 2025.
Pharmasaga will also launch the same small molecule (re-named as PS-002) for the treatment of T1D in 2022 to increase our product pipeline.
US FDA approved the application of investigation drug (IND), PS-001. We are scheduled to start phase 1 clinical trial of PS-001 by the third quarter of 2022 and complete it by the end of 2022. Its phase 2 clinical trial is scheduled to start in 2023 and complete it by the end of 2025.
Pharmasaga will also launch the same small molecule (re-named as PS-002) for the treatment of T1D in 2022 to increase our product pipeline.
Founded Year
2021
Unified Business No.
83379922
Status
Active
Number of Employees
0
Total Paid-in
Capital
535,365,800 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Pharmasaga is a spin-off of Academia Sinica and was founded in Jan 2021. Our core technology is a drug discovery platform composed of molecular docking, chemistry and biology for drug discovery, developed by Dr Wen-Chin Yang, Academia Sinica. With this platform, we developed first-in-class Pdia4 inhibitors for diabetes. The Pdia4 inhibitors can be used as a brand-new beta cell-centric approach to reducing beta cell failure and, in turn, diabetes. More importantly, the Pdia4 inhibitors can reverse diabetes alone and in combination with metformin.
